基于表面等离子体子共振成像技术研究苏拉明和顺铂对肝癌细胞生长的抑制作用

基于表面等离子体子共振成像(SPRi)技术提出了一种实时、 非标记的新型抗癌药物药效评估方法. 以聚二甲基硅氧烷(PDMS)为材料, 制作了包含微柱结构的微流控芯片作为流通反应池, 配合自行设计组装的SPRi生物传感器完成肿瘤细胞的特异性捕获及检测, 研究了苏拉明和顺铂对肝癌细胞HepG2的生长抑制作用. 同时引入辅助验证实验, 即采用常规八肽胆囊收缩素(简称CCK-8)法测定上述药物对肝癌细胞增殖的抑制作用. SPRi检测结果表明, 苏拉明和顺铂能抑制肿瘤细胞HepG2增殖并呈现剂量、 时间依赖关系.     

吡唑锌配合物的合成、晶体结构及抗肝癌细胞活性

通过溶剂挥发法合成了锌配合物[Zn(Hppo)2(ppo)Cl](1),Hppo=5-苯基-3-羟基吡唑,利用元素分析、FTIR以及X射线衍射法对配合物1进行表征。晶体结构显示配合物属于单斜晶系,P21空间群。检测了配合物1对肝癌细胞HepG2、Hep3B和Huh7的细胞形态与细胞毒性的影响,结果表明配合物1对肿瘤细胞具有明显的抑制作用。     

海洋珍珠生物提取液单独与顺铂联合对人宫颈癌Siha细胞的生长抑制作用

为探讨海洋珍珠生物提取液对人宫颈癌Siha细胞体外生长的抑制作用,以及海洋珍珠生物提取液增加Siha细胞对顺铂的敏感性,以期对治疗宫颈癌及其它肿瘤寻找新的治疗药物,体外培养人宫颈癌Siha细胞,分别用海洋珍珠生物提取液、顺铂、海洋珍珠生物提取液加顺铂处理24、48、72 h,采用四甲基偶氮唑蓝(MTT)比色法检测海洋珍珠生物提取液和顺铂及两者联合应用Siha细胞的存活率。结果表明,海洋珍珠生物提取液对Siha细胞的增殖有明显的抑制作用(P0.01),其处理,24、48、72 h的IC50分别为56.26、51.92、48.92μg/mL,顺铂对Siha细胞的24、48、72 h的IC50分别为16.74、4.68、6.69μg/mL;两者合用可大大提高对Siha细胞的抑制作用,比单用海洋珍珠生物提取液或单用顺铂均有明显的提高(P0.01)。提示海洋珍珠生物提取液能抑制Siha细胞的生长,同时能增加Siha细胞对顺铂的敏感性。     

蒽醌-多胺缀合物的合成及生理活性研究

设计合成7个蒽醌-多胺缀合物,化合物结构经1H NMR,APCI-MS和元素分析确认.利用MTT(噻唑蓝)法测试7个目标化合物对K562,HepG2,MB231,Hela,HCT-116五种肿瘤细胞的体外细胞毒性,结果表明所合成的化合物对测肿瘤细胞均具有明显的生长抑制作用.DNA结合实验表明11b和14c以嵌入方式作用于DNA,使鲱鱼精DNA-EB体系的荧光产生猝灭现象.     

3-[(4'-吗啉基)-羰基或乙氧羰基]-4-苯氨基喹啉化合物的合成及抗肿瘤活性

以间氯苯胺与乙氧基亚甲基丙二酸二乙酯(EMME)为原料, 经缩合、 高温环合、 水解、 氯代和亲核取代等反应设计并合成了16个3位为(4'-吗啉)-羰基或乙氧羰基的4-苯氨基喹啉化合物(Ⅰ₁~Ⅰ₁₀, Ⅱ₁~Ⅱ₆). 目标化合物结构经MS及¹H NMR确证. 以MTT法, 采用表皮生长因子受体(EGFRs)高表达的人癌细胞(HeLa, HepG2, BGC-823)对目标化合物进行活性测试, 结果表明, 该类化合物对HeLa, HepG2和BGC-823细胞增殖具有一定程度的抑制作用. 其中化合物Ⅱ₄~Ⅱ₆ 对 HepG2 细胞抑制作用较强, 化合物Ⅱ₁和Ⅱ₅对BGC-823细胞抑制作用较强. 初步探讨了化合物结构与生物活性的关系.     

多功能芯片对合成样本中肝癌细胞HepG2的测试研究

设计并制作了一种集多孔流分离(Multi-orifice flow fractionation,MOFF)技术与磁捕获技术于一体的用于特异性分离和捕获合成样本中肝癌细胞HepG2的多功能微流控细胞芯片.此芯片由玻璃基片和PDMS微通道盖片组成,PDMS盖片上含有3条进样通道、MOFF分离区和六边形腔体的细胞富集检测区.其中,MOFF分离区总长20 mm,由80组长度为0.18 mm、深度为50μm、收缩区域宽度为0.06 mm、扩张区域宽度为0.20 mm的半菱形收缩/扩张重复单元组成,每组收缩/扩张重复单元间的夹角为103.0°.实验以肝癌细胞HepG2-血细胞混悬液为样本;根据磁珠表面修饰c-Met抗体能与肝癌细胞HepG2特异性结合的原理,通过表面羧基化的磁珠、EDC(1 mg/mL)、NHS(1 mg/mL)和c-Met抗体制备了浓度为50μg/mL的免疫磁珠(Anti-MNCs)悬浮液.在样本流速为50μL/min条件下,利用外加磁场实现了血细胞合成样本中微量肝癌细胞HepG2的有效捕获;采用微波加热法以柠檬酸、硫脲为原料制备了用于荧光标记HepG2的碳量子点,在芯片上实现了血液中肝癌细胞HepG2的原位荧光可视化观测.对芯片检测区捕获到的HepG2进行了显微计数分析,对500μL血细胞(107 cell/mL)中含10个HepG2细胞的合成样本,捕获效率达到88.5%±6.7%(n=20).结果表明,所设计的多模式多功能的微流控芯片具有良好的肿瘤细胞分离和检测功能.     

C-13位烷氧基赤霉素衍生物的合成与抗肿瘤活性研究

设计并合成了系列C-13位为醚结构且在A环和D环有两个α,β-不饱和酮结构的赤霉素衍生物.采用噻唑蓝(MTT)法评价了其对人肺腺癌细胞(A549)、人肝癌细胞(HepG2)、人胃癌细胞(MKN28)以及结肠癌细胞(HT29)的体外生长抑制作用,结果表明:此类化合物都有较强的体外抗肿瘤活性,其中化合物27的活性最强(对人胃癌细胞MKN28的IC50=0.21μmol·L-1),优于阳性对照药物顺铂(DDP).     

4-二甲氨基黄酮衍生物的合成及其活性评价

设计合成了10个4-二甲氨基黄酮衍生物,产物结构均经1H NMR,ESI-MS和元素分析确认.采用噻唑蓝(MTT)法测试了化合物对HepG2(人肝癌细胞)的抑制作用,结果表明目标化合物在30μmol/L浓度下对HepG2细胞损伤均有一定的抑制作用,大部分化合物优于对照药物槲皮素,其中化合物5c,5e,5f和5j活性最强,抑制率分别为91.0%,90.1%,95.7%和92.1%,而且化合物5f在10μmol/L浓度下对HepG2的抑制率为93.1%,具有深入研究的价值.     

小檗碱与和厚朴酚及槲皮素缀合物的合成及其体外抗肝癌HepG2细胞活性评价（英文）

小檗碱、和厚朴酚、槲皮素都是具有良好抗肿瘤活性的先导化合物,以其为原料合成了三个新型化合物,通过~1H NMR、~(13)C NMR、2D NMR、HRMS、IR和UV等方法对目标化合物进行结构确证;体外抗HepG2肝癌细胞活性结果显示,两个化合物对Hep G2肝癌细胞的抑制作用远远优于原料药和厚朴酚与盐酸小檗碱,且活性与阳性对照药顺铂相当,有望成为潜在的抗肿瘤药物.     

水溶性的半胱氨酸-β-环糊精铂配合物的合成及生物活性研究

利用半胱氨酸修饰的β-环糊精与K2PtCl4反应得到了水溶性的铂配合物(Pt(L-Cys-β-CD)Cl_2).通过质谱、元素分析和核磁等手段对合成的铂配合物进行表征.利用MTT法对该铂配合物的抗肿瘤活性进行研究.主要选择K562,HepG2和7701三种细胞对这种铂配合物的细胞毒性进行研究,结果表明该铂配合物具有较高的细胞抑制率.其在K562细胞中的IC50值为(89.5±2.6)μmol/L.更有意义的是,这种铂配合物对正常细胞7701的细胞毒性要明显低于另外两种癌细胞.因此,该类铂配合物有望作为潜在的抗肿瘤药物.     

Tumor Cell Detection Device Based on Surface Plasmon Resonance Imaging and Image Processing

A laboratory-made tumor cell detection device was fabricated based on both surface plasmon resonance imaging（SPRi） and image processing.In this device,a gravity-induced flow injection chip（gFIC） was exploited to replace a pump.Also two charge coupled devices（CCDs） were used to detect HepG2 cells by SPRi and image processing,respectively.The results of two CCDs are associated.Protein A was used to modify the sensing surface.The inlet angle was carefully adjusted for the device to get an enhanced image.In the test,the contrast among cell solutions at different concentrations can be easily distinguished.The other CCD using image processing can tell false-positive in some degree.This detection is label-free,real time,and precise.     

Synergistic Growth-Suppressive Effects of Quercetin and Cisplatin on HepG2 Human Hepatocellular Carcinoma Cells

Quercetin, a natural flavonoid, exhibits anticancer effects. The aim of this study is to determine whether the combination of quercetin with cisplatin, a conventional chemotherapeutic drug, would have synergistic suppressive effects on hepatocellular carcinoma (HCC) cells. To this end, HepG2 cells were exposed to quercetin (50 μM) or cisplatin (10 μM) alone or combination of both and cell proliferation and apoptosis were investigated. Our data revealed that the combination of quercetin and cisplatin was significantly (P?<?0.05) effective in inducing growth suppression and apoptosis in HepG2 cells, when compared with single agent treatment. Quercetin combined with cisplatin modulated the expression of numerous genes involved in cell cycle progression and apoptosis. Treatment with quercetin rather than cisplatin resulted in a marked elevation of p16 expression in HepG2 cells. Targeted reduction of p16 using RNA interference technology partially reversed quercetin-induced cell cycle G1 arrest and apoptosis in HepG2 cells. In conclusion, quercetin has suppressive activity against HCC cells through p16-mediated cell cycle arrest and apoptosis and its combination with cisplatin yielded synergistic inhibitory effects in suppressing cell growth and inducing apoptosis.     

An on-chip intestine-liver model for multiple drugs absorption and metabolism behavior simulation

A double-layer microfluidic chip integrated with a hollow fiber(HF)was developed to reconstitute the intestine-liver functionality for studying the absorption and metabolism of combination drugs.Caco-2 cells were inoculated in the HF cavity at the top of the serpentine channel to simulate the intestinal tissue for drug absorption and transport studied,and Hep G2 cells,seeded in the bottom chamber,were used to mimic the liver for metabolism-related studies.Genistein and dacarbazine were selected for combination drug therapy and its effects on cell viability,hepatotoxicity,and cell cycle arrest under drug-conditioned culture were investigated.The results suggested that the combined concentration below-100μg/m L had no significant inhibitory effect on Hep G2 cell viability,and therefore Hep G2 cells maintained their drug metabolism ability.When the drug concentration was increased above 250μg/m L,Hep G2 cells underwent apoptosis.Detection of metabolites by mass spectrometry proved the effective metabolism in the microchip model.This dynamic,co-culture microchip successfully provided a podium for long-term observation of absorption,transport,and metabolism of combination drugs,and could be an effective in vitro simulation model for further clinical research.     

Dielectrophoresis-based cellular microarray chip for anticancer drug screening in perfusion microenvironments

We present a dielectrophoresis (DEP)-based cellular microarray chip for cell-based anticancer drug screening in perfusion microenvironments. Human breast cancer cells, MCF7, were seeded into the chip and patterned via DEP forces onto the planar interdigitated ring electrode (PIRE) arrays. Roughly, only one third of the cell amount was required for the chip compared to that for a 96-well plate control. Drug concentrations (cisplatin or docetaxel) were stably generated by functional integration of a concentration gradient generator (CGG) and an anti-crosstalk valve (ACV) to treat cells for 24 hours. Cell viability was quantified using a dual staining method. Results of cell patterning show substantial uniformity of patterned cells (92 ± 5 cells per PIRE). Furthermore, after 24 hour drug perfusion, no statistical significance in dose-responses between the chip and the 96-well plate controls was found. The IC(50) value from the chip also concurred with the values from the literature. Moreover, the perfusion culture exhibited reproducibility of drug responses of cells on different PIREs in the same chamber. The chip would enable applications where cells are of limited supply, and supplement microfluidic perfusion cultures for clinical practices.     

微流控细胞芯片LED诱导荧光检测微系统

基于微流控细胞芯片分析技术和微机电系统(MEMS)加工技术, 设计制作了阵列式微流控细胞检测芯片, 采用自组装的顶窗型光电倍增管(PMT)和信号采集电路采集芯片微管道内流动细胞的荧光信号, 构建了一种针对低浓度细胞悬浮液的微流控细胞芯片发光二极管(LED)诱导荧光的快速检测微系统, 实现了对低浓度(≤40 Cell/mL)荧光标记的HepG2肝癌细胞悬浮液样本的定量计数和测试, 而且在血液细胞共存的条件下, 仍可以有效地对血液中少量HepG2肝癌细胞进行荧光计数和测试. 整个系统结构简单, 操作方便且检测灵敏度较高.     

Inflammatory mimetic microfluidic chip by immobilization of cell adhesion molecules for T cell adhesion

Leukocyte adhesion to adhesion molecules on endothelial cells is important in immune function, cancer metastasis and inflammation. This cell-cell binding is mediated via cell adhesion molecules such as E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) found on endothelial cells. Because these adhesion molecules on endothelial cells vary significantly across several disease conditions such as autoimmune diseases, inflammation or cancer metastasis, investigations of therapeutic agents that down-regulate leukocyte-endothelial interactions have been based on in vitro models using endothelial cell lines. Here we report a new model, an inflammatory mimetic microfluidic chip, which emulates leukocyte binding to cell adhesion molecules (CAM) by controlling the types and ratio of adhesion molecules. In our model, E-selectin was essential for the synergic binding of Jurkat T cells. Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine A (CsA), were used to inhibit T cell interactions under the physiologic model of T cell migration at a ratio of 5?:?4.3?:?3.9 (E-selectin?:?ICAM-1?:?VCAM-1). Our results support the potential usefulness of the inflammatory mimetic microfluidic chip as a T cell adhesion assay tool with modified adhesion molecules for applications such as immunosuppressive drug screening. The inflammatory mimetic microfluidic chip can also be used as a biosensor in clinical diagnostics, drug efficacy tests and high throughput drug screening due to the dynamic monitoring capability of the microfluidic chip.     

微流控芯片药物诱导细胞凋亡

发展了一种以微流控芯片为平台的药物诱导细胞凋亡的新方法.选择HeLa细胞为对象,通过浓度梯度芯片形成稳定的药物浓度梯度,诱导HeLa细胞凋亡,利用荧光能量共振转移（fluorescence resonance energy transfer,FRET）成像系统进行实时监测,分析细胞对不同浓度化合物的毒性反应.结果表明,细胞在顺铂诱导下发生明显的起泡和皱缩,FRET比率值逐渐降低,在药物浓度梯度作用下,芯片每个通道内细胞呈现不同程度的凋亡.该方法实现了药物浓度梯度诱导细胞凋亡的实时监测和定量分析,为抗肿瘤药物评价和高通量药物筛选提供了新的手段.     

Design of parallel microfluidic gradient-generating networks for studying cellular response to chemical stimuli

A microfluidic chip featuring laminar flow-based parallel gradient-generating networks was designed and fabricated. The microchip contains 5 gradient generators and 30 cell chambers where the resulting concentration gradients of drugs are delivered to stimulate on-chip cultured cells. The microfluidics exploits the advantage of lab-on-a-chip technology by integrating the generation of drug concentration gradients and a series of cell operations including seeding, culture, stimulation and staining into a chip. The microfluidic network was patterned on a glass wafer, which was further bonded to a PDMS film. A series of weir structures were fabricated on the cell culture reservoir to facilitate cell positioning and seeding. Cell injection and fluid delivery were controlled by a syringe pump. Steady parallel concentration gradients were generated by flowing two fluids in each network. Over time observation shows that the microchip was suitable for cell seeding and culture. The microchip described above was applied in studying the role of reduced glutathione (GSH) in mediating chemotherapy sensitivity of MCF-7 cells. MCF-7 cells were treated with concentration gradients of As₂O₃ and N-acetyl cysteine (NAC) for GSH modulation, followed by exposure to adriamycin. GSH levels were down-regulated upon As₂O₃ treatment and up-regulated upon NAC treatment. Suppression of intracellular GSH by treatment with As₂O₃ has been shown to increase sensitivity to adriamycin. Conversely, elevation of intracellular GSH by treatment with NAC leads to increased drug resistance. The integrated microfluidic chip is able to perform multiparametric pharmacological profiling with easy operation, and thus holds great potential for extrapolation to the cell based high-content drug screening. __________ Translated from Chinese Journal of Analytical Chemistry, 2008, 36(2): 143–149